Abstract
Summary
Etanercept is a medication used to manage and treat autoimmune conditions such as plaque psoriasis, rheumatoid arthritis, psoriatic arthritis, juvenile idiopathic arthritis, and ankylosing spondylitis. It is a biologic fusion protein in the TNF blocker class of medications.
The global market for Enbrel (Etanercept) Biosimilar was estimated to be worth US$ 1247 million in 2025 and is forecast to a readjusted size of US$ 1707.3 million by 2032 with a CAGR of 4.6% during the forecast period 2026-2032
North American market for Enbrel (Etanercept) Biosimilar was valued at $ million in 2025 and will reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
Asia-Pacific market for Enbrel (Etanercept) Biosimilar was valued at $ million in 2025 and will reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
Europe market for Enbrel (Etanercept) Biosimilar was valued at $ million in 2025 and will reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
The global key companies of Enbrel (Etanercept) Biosimilar include Samsung Bioepis, Novartis, 3s Bio and Lupin, etc. In 2025, the global five largest players hold a share approximately % in terms of revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Enbrel (Etanercept) Biosimilar, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Enbrel (Etanercept) Biosimilar by region & country, by Type, and by Application.
The Enbrel (Etanercept) Biosimilar market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2025 as the base year, with history and forecast data for the period from 2021 to 2032. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Enbrel (Etanercept) Biosimilar.
Market Segmentation
By Company
Samsung Bioepis
Novartis
3s Bio
Lupin
Segment by Type:
Syringe
Pen
Segment by Application
Hospital
Pharmacy
Other
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Enbrel (Etanercept) Biosimilar manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Enbrel (Etanercept) Biosimilar in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Enbrel (Etanercept) Biosimilar in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
The global market for Enbrel (Etanercept) Biosimilar was estimated to be worth US$ 1247 million in 2025 and is forecast to a readjusted size of US$ 1707.3 million by 2032 with a CAGR of 4.6% during the forecast period 2026-2032
North American market for Enbrel (Etanercept) Biosimilar was valued at $ million in 2025 and will reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
Asia-Pacific market for Enbrel (Etanercept) Biosimilar was valued at $ million in 2025 and will reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
Europe market for Enbrel (Etanercept) Biosimilar was valued at $ million in 2025 and will reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
The global key companies of Enbrel (Etanercept) Biosimilar include Samsung Bioepis, Novartis, 3s Bio and Lupin, etc. In 2025, the global five largest players hold a share approximately % in terms of revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Enbrel (Etanercept) Biosimilar, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Enbrel (Etanercept) Biosimilar by region & country, by Type, and by Application.
The Enbrel (Etanercept) Biosimilar market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2025 as the base year, with history and forecast data for the period from 2021 to 2032. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Enbrel (Etanercept) Biosimilar.
Market Segmentation
By Company
Samsung Bioepis
Novartis
3s Bio
Lupin
Segment by Type:
Syringe
Pen
Segment by Application
Hospital
Pharmacy
Other
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Enbrel (Etanercept) Biosimilar manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Enbrel (Etanercept) Biosimilar in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Enbrel (Etanercept) Biosimilar in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Table of Contents
1 Market Overview
1.1 Enbrel (Etanercept) Biosimilar Product Introduction
1.2 Global Enbrel (Etanercept) Biosimilar Market Size Forecast
1.2.1 Global Enbrel (Etanercept) Biosimilar Sales Value (2021-2032)
1.2.2 Global Enbrel (Etanercept) Biosimilar Sales Volume (2021-2032)
1.2.3 Global Enbrel (Etanercept) Biosimilar Sales Price (2021-2032)
1.3 Enbrel (Etanercept) Biosimilar Market Trends & Drivers
1.3.1 Enbrel (Etanercept) Biosimilar Industry Trends
1.3.2 Enbrel (Etanercept) Biosimilar Market Drivers & Opportunity
1.3.3 Enbrel (Etanercept) Biosimilar Market Challenges
1.3.4 Enbrel (Etanercept) Biosimilar Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Enbrel (Etanercept) Biosimilar Players Revenue Ranking (2025)
2.2 Global Enbrel (Etanercept) Biosimilar Revenue by Company (2021-2026)
2.3 Global Enbrel (Etanercept) Biosimilar Players Sales Volume Ranking (2025)
2.4 Global Enbrel (Etanercept) Biosimilar Sales Volume by Company Players (2021-2026)
2.5 Global Enbrel (Etanercept) Biosimilar Average Price by Company (2021-2026)
2.6 Key Manufacturers Enbrel (Etanercept) Biosimilar Manufacturing Base Distribution and Headquarters
2.7 Key Manufacturers Enbrel (Etanercept) Biosimilar Product Offered
2.8 Key Manufacturers Time to Begin Mass Production of Enbrel (Etanercept) Biosimilar
2.9 Enbrel (Etanercept) Biosimilar Market Competitive Analysis
2.9.1 Enbrel (Etanercept) Biosimilar Market Concentration Rate (2021-2026)
2.9.2 Global 5 and 10 Largest Manufacturers by Enbrel (Etanercept) Biosimilar Revenue in 2025
2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Enbrel (Etanercept) Biosimilar as of 2025)
2.10 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Syringe
3.1.2 Pen
3.2 Global Enbrel (Etanercept) Biosimilar Sales Value by Type
3.2.1 Global Enbrel (Etanercept) Biosimilar Sales Value by Type (2021 VS 2025 VS 2032)
3.2.2 Global Enbrel (Etanercept) Biosimilar Sales Value, by Type (2021-2032)
3.2.3 Global Enbrel (Etanercept) Biosimilar Sales Value, by Type (%) (2021-2032)
3.3 Global Enbrel (Etanercept) Biosimilar Sales Volume by Type
3.3.1 Global Enbrel (Etanercept) Biosimilar Sales Volume by Type (2021 VS 2025 VS 2032)
3.3.2 Global Enbrel (Etanercept) Biosimilar Sales Volume, by Type (2021-2032)
3.3.3 Global Enbrel (Etanercept) Biosimilar Sales Volume, by Type (%) (2021-2032)
3.4 Global Enbrel (Etanercept) Biosimilar Average Price by Type (2021-2032)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Hospital
4.1.2 Pharmacy
4.1.3 Other
4.2 Global Enbrel (Etanercept) Biosimilar Sales Value by Application
4.2.1 Global Enbrel (Etanercept) Biosimilar Sales Value by Application (2021 VS 2025 VS 2032)
4.2.2 Global Enbrel (Etanercept) Biosimilar Sales Value, by Application (2021-2032)
4.2.3 Global Enbrel (Etanercept) Biosimilar Sales Value, by Application (%) (2021-2032)
4.3 Global Enbrel (Etanercept) Biosimilar Sales Volume by Application
4.3.1 Global Enbrel (Etanercept) Biosimilar Sales Volume by Application (2021 VS 2025 VS 2032)
4.3.2 Global Enbrel (Etanercept) Biosimilar Sales Volume, by Application (2021-2032)
4.3.3 Global Enbrel (Etanercept) Biosimilar Sales Volume, by Application (%) (2021-2032)
4.4 Global Enbrel (Etanercept) Biosimilar Average Price by Application (2021-2032)
5 Segmentation by Region
5.1 Global Enbrel (Etanercept) Biosimilar Sales Value by Region
5.1.1 Global Enbrel (Etanercept) Biosimilar Sales Value by Region: 2021 VS 2025 VS 2032
5.1.2 Global Enbrel (Etanercept) Biosimilar Sales Value by Region (2021-2026)
5.1.3 Global Enbrel (Etanercept) Biosimilar Sales Value by Region (2027-2032)
5.1.4 Global Enbrel (Etanercept) Biosimilar Sales Value by Region (%), (2021-2032)
5.2 Global Enbrel (Etanercept) Biosimilar Sales Volume by Region
5.2.1 Global Enbrel (Etanercept) Biosimilar Sales Volume by Region: 2021 VS 2025 VS 2032
5.2.2 Global Enbrel (Etanercept) Biosimilar Sales Volume by Region (2021-2026)
5.2.3 Global Enbrel (Etanercept) Biosimilar Sales Volume by Region (2027-2032)
5.2.4 Global Enbrel (Etanercept) Biosimilar Sales Volume by Region (%), (2021-2032)
5.3 Global Enbrel (Etanercept) Biosimilar Average Price by Region (2021-2032)
5.4 North America
5.4.1 North America Enbrel (Etanercept) Biosimilar Sales Value, 2021-2032
5.4.2 North America Enbrel (Etanercept) Biosimilar Sales Value by Country (%), 2025 VS 2032
5.5 Europe
5.5.1 Europe Enbrel (Etanercept) Biosimilar Sales Value, 2021-2032
5.5.2 Europe Enbrel (Etanercept) Biosimilar Sales Value by Country (%), 2025 VS 2032
5.6 Asia Pacific
5.6.1 Asia Pacific Enbrel (Etanercept) Biosimilar Sales Value, 2021-2032
5.6.2 Asia Pacific Enbrel (Etanercept) Biosimilar Sales Value by Country (%), 2025 VS 2032
5.7 South America
5.7.1 South America Enbrel (Etanercept) Biosimilar Sales Value, 2021-2032
5.7.2 South America Enbrel (Etanercept) Biosimilar Sales Value by Country (%), 2025 VS 2032
5.8 Middle East & Africa
5.8.1 Middle East & Africa Enbrel (Etanercept) Biosimilar Sales Value, 2021-2032
5.8.2 Middle East & Africa Enbrel (Etanercept) Biosimilar Sales Value by Country (%), 2025 VS 2032
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Enbrel (Etanercept) Biosimilar Sales Value Growth Trends, 2021 VS 2025 VS 2032
6.2 Key Countries/Regions Enbrel (Etanercept) Biosimilar Sales Value
6.2.1 Key Countries/Regions Enbrel (Etanercept) Biosimilar Sales Value, 2021-2032
6.2.2 Key Countries/Regions Enbrel (Etanercept) Biosimilar Sales Volume, 2021-2032
6.3 United States
6.3.1 United States Enbrel (Etanercept) Biosimilar Sales Value, 2021-2032
6.3.2 United States Enbrel (Etanercept) Biosimilar Sales Value by Type (%), 2025 VS 2032
6.3.3 United States Enbrel (Etanercept) Biosimilar Sales Value by Application, 2025 VS 2032
6.4 Europe
6.4.1 Europe Enbrel (Etanercept) Biosimilar Sales Value, 2021-2032
6.4.2 Europe Enbrel (Etanercept) Biosimilar Sales Value by Type (%), 2025 VS 2032
6.4.3 Europe Enbrel (Etanercept) Biosimilar Sales Value by Application, 2025 VS 2032
6.5 China
6.5.1 China Enbrel (Etanercept) Biosimilar Sales Value, 2021-2032
6.5.2 China Enbrel (Etanercept) Biosimilar Sales Value by Type (%), 2025 VS 2032
6.5.3 China Enbrel (Etanercept) Biosimilar Sales Value by Application, 2025 VS 2032
6.6 Japan
6.6.1 Japan Enbrel (Etanercept) Biosimilar Sales Value, 2021-2032
6.6.2 Japan Enbrel (Etanercept) Biosimilar Sales Value by Type (%), 2025 VS 2032
6.6.3 Japan Enbrel (Etanercept) Biosimilar Sales Value by Application, 2025 VS 2032
6.7 South Korea
6.7.1 South Korea Enbrel (Etanercept) Biosimilar Sales Value, 2021-2032
6.7.2 South Korea Enbrel (Etanercept) Biosimilar Sales Value by Type (%), 2025 VS 2032
6.7.3 South Korea Enbrel (Etanercept) Biosimilar Sales Value by Application, 2025 VS 2032
6.8 Southeast Asia
6.8.1 Southeast Asia Enbrel (Etanercept) Biosimilar Sales Value, 2021-2032
6.8.2 Southeast Asia Enbrel (Etanercept) Biosimilar Sales Value by Type (%), 2025 VS 2032
6.8.3 Southeast Asia Enbrel (Etanercept) Biosimilar Sales Value by Application, 2025 VS 2032
6.9 India
6.9.1 India Enbrel (Etanercept) Biosimilar Sales Value, 2021-2032
6.9.2 India Enbrel (Etanercept) Biosimilar Sales Value by Type (%), 2025 VS 2032
6.9.3 India Enbrel (Etanercept) Biosimilar Sales Value by Application, 2025 VS 2032
7 Company Profiles
7.1 Samsung Bioepis
7.1.1 Samsung Bioepis Company Information
7.1.2 Samsung Bioepis Introduction and Business Overview
7.1.3 Samsung Bioepis Enbrel (Etanercept) Biosimilar Sales, Revenue and Gross Margin (2021-2026)
7.1.4 Samsung Bioepis Enbrel (Etanercept) Biosimilar Product Offerings
7.1.5 Samsung Bioepis Recent Development
7.2 Novartis
7.2.1 Novartis Company Information
7.2.2 Novartis Introduction and Business Overview
7.2.3 Novartis Enbrel (Etanercept) Biosimilar Sales, Revenue and Gross Margin (2021-2026)
7.2.4 Novartis Enbrel (Etanercept) Biosimilar Product Offerings
7.2.5 Novartis Recent Development
7.3 3s Bio
7.3.1 3s Bio Company Information
7.3.2 3s Bio Introduction and Business Overview
7.3.3 3s Bio Enbrel (Etanercept) Biosimilar Sales, Revenue and Gross Margin (2021-2026)
7.3.4 3s Bio Enbrel (Etanercept) Biosimilar Product Offerings
7.3.5 3s Bio Recent Development
7.4 Lupin
7.4.1 Lupin Company Information
7.4.2 Lupin Introduction and Business Overview
7.4.3 Lupin Enbrel (Etanercept) Biosimilar Sales, Revenue and Gross Margin (2021-2026)
7.4.4 Lupin Enbrel (Etanercept) Biosimilar Product Offerings
7.4.5 Lupin Recent Development
8 Industry Chain Analysis
8.1 Enbrel (Etanercept) Biosimilar Industrial Chain
8.2 Enbrel (Etanercept) Biosimilar Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Enbrel (Etanercept) Biosimilar Sales Model
8.5.2 Sales Channel
8.5.3 Enbrel (Etanercept) Biosimilar Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer